Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin--a case report

Dyslipidemia is a major risk factor for the development of cardiovascular diseases and statins are the common drugs used to correct dyslipidemia. Herein, we report a case where the subject was a nondiabetic, dyslipidemia patient on medication with Rosuvastatin. After the intake of Rosuvastatin, his...

Full description

Saved in:
Bibliographic Details
Published inJournal of dietary supplements Vol. 11; no. 1; p. 1
Main Authors Ganesh, Jegatheesan Saravana, Rao, Yegneswara Yellury, Ravikumar, Ratnagiri, Jayakrishnan, Gosalakkal A, Iwasaki, Masaru, Preethy, Senthilkumar, Abraham, Samuel J K
Format Journal Article
LanguageEnglish
Published England 01.03.2014
Subjects
Online AccessGet more information
ISSN1939-022X
DOI10.3109/19390211.2013.859211

Cover

Loading…
More Information
Summary:Dyslipidemia is a major risk factor for the development of cardiovascular diseases and statins are the common drugs used to correct dyslipidemia. Herein, we report a case where the subject was a nondiabetic, dyslipidemia patient on medication with Rosuvastatin. After the intake of Rosuvastatin, his triglycerides decreased to a minimum of 220 mg/dL. In order to augment the action of Rosuvastatin, he was advised to take 1.5 mg of Nichi Glucan food supplement, which is a 1,3-1,6 Beta Glucan derived from the black yeast, Aureobasidium pullulans, daily for 2 months. At the end of 2 months, his triglyceride levels decreased from 523 mg/dL (at start of the study) to 175 mg/dL. His VLDL levels, which were 104.6 mg/dL at the start of the study decreased to 35 mg/dL and the HDL cholesterol levels increased from 27 to 38 mg/dL. This is a first of its kind report on the effect of the black yeast derived 1,3-1,6 Beta Glucans on dyslipidemia not associated with diabetes. Thus supplementation of Nichi Glucan, 1,3- 1,6 Beta Glucan derived from the black yeast along with the routine medications was beneficial to treat dyslipidemia and a larger trial is needed to confirm the effects.
ISSN:1939-022X
DOI:10.3109/19390211.2013.859211